Retracted: Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with EGFR-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status

Detalles Bibliográficos
Autor principal: and Alternative Medicine, Evidence-Based Complementary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Retraction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356200/
https://www.ncbi.nlm.nih.gov/pubmed/37476338
http://dx.doi.org/10.1155/2023/9789654
_version_ 1785075212009603072
author and Alternative Medicine, Evidence-Based Complementary
author_facet and Alternative Medicine, Evidence-Based Complementary
author_sort and Alternative Medicine, Evidence-Based Complementary
collection PubMed
description
format Online
Article
Text
id pubmed-10356200
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-103562002023-07-20 Retracted: Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with EGFR-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status and Alternative Medicine, Evidence-Based Complementary Evid Based Complement Alternat Med Retraction Hindawi 2023-07-12 /pmc/articles/PMC10356200/ /pubmed/37476338 http://dx.doi.org/10.1155/2023/9789654 Text en Copyright © 2023 Evidence-Based Complementary and Alternative Medicine. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Retraction
and Alternative Medicine, Evidence-Based Complementary
Retracted: Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with EGFR-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status
title Retracted: Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with EGFR-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status
title_full Retracted: Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with EGFR-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status
title_fullStr Retracted: Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with EGFR-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status
title_full_unstemmed Retracted: Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with EGFR-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status
title_short Retracted: Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with EGFR-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status
title_sort retracted: osimertinib improves overall survival in patients with leptomeningeal metastases associated with egfr-mutated non-small-cell lung cancer regardless of cerebrospinal fluid t790m mutational status
topic Retraction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356200/
https://www.ncbi.nlm.nih.gov/pubmed/37476338
http://dx.doi.org/10.1155/2023/9789654
work_keys_str_mv AT andalternativemedicineevidencebasedcomplementary retractedosimertinibimprovesoverallsurvivalinpatientswithleptomeningealmetastasesassociatedwithegfrmutatednonsmallcelllungcancerregardlessofcerebrospinalfluidt790mmutationalstatus

Ejemplares similares